CellSource Co (TSE:4880) Total Equity: 円5,993 Mil (As of Apr. 2026)


TSE:4880 CellSource Co Ltd TSE:4880
69 GF Score
Price 円319.00
GF Value 円781.48
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is CellSource Co Total Equity?

CellSource Co TSE:4880 -2.15% 69 Total Equity is 円5,993 Mil as of Apr. 2026. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review.

CellSource Co's total equity for the quarter that ended in Apr. 2026 was 円5,993 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

CellSource Co Total Equity Historical Data

* Premium members only.

The historical data trend for CellSource Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellSource Co Total Equity Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Total Equity
Get a 7-Day Free Trial Premium Member Only 2,720.35 3,785.53 6,202.00 6,037.10 6,016.82

CellSource Co Semi-Annual Data
Oct17 Oct18 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25 Apr26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,096.73 6,037.10 5,947.64 6,016.82 5,992.76
TSE:4880
69GF Score
CellSource Co Ltd TSE:4880
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellSource Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

CellSource Co's Total Equity for the fiscal year that ended in Oct. 2025 is calculated as

Total Equity=Total Assets(Q: Oct. 2025 )-Total Liabilities(Q: Oct. 2025 )
=7023.969-1007.145
=6,017

CellSource Co's Total Equity for the quarter that ended in Apr. 2026 is calculated as

Total Equity=Total Assets(Q: Apr. 2026 )-Total Liabilities(Q: Apr. 2026 )
=6984.466-991.709
=5,993

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of 円5,993 Mil mean?
CellSource Co (TSE:4880) has a Total Equity of 円5,993 Mil as of Apr. 2026. The total amount of equity as record on a company's balance sheet. View historical data for CellSource Co and its competitors.
Is CellSource Co's Total Equity too high?
CellSource Co's current Total Equity is 円5,993 Mil. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Total Equity compare to VRTX and REGN?
CellSource Co's Total Equity of 円5,993 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for CellSource Co and its competitors. CellSource Co's current Total Equity is 円5,993 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current Total Equity is 円5,993 Mil. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Total Equity is 円5,993 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellSource Co (TSE:4880) Overvalued in 2026?

Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued. The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48. GuruFocus considers CellSource Co to be Significantly Undervalued.

Key valuation signals for TSE:4880:

  • Total Equity: 円5,993 Mil
  • GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellSource Co Business Description

Address Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score

Get the complete analysis for TSE:4880

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円319.00
Price
円781.48
GF Value